Predilife S.A.

Paris Stock Exchange ALPRE.PA

Predilife S.A. Operating Cash Flow for the year ending December 31, 2023: USD -4.67 M

Predilife S.A. Operating Cash Flow is USD -4.67 M for the year ending December 31, 2023, a -42.34% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Predilife S.A. Operating Cash Flow for the year ending December 31, 2022 was USD -3.28 M, a 24.73% change year over year.
Predilife S.A. Operating Cash Flow for the year ending December 31, 2021 was USD -4.36 M, a -69.13% change year over year.
Predilife S.A. Operating Cash Flow for the year ending December 31, 2020 was USD -2.58 M, a 4.14% change year over year.
Predilife S.A. Operating Cash Flow for the year ending December 31, 2019 was USD -2.69 M, a -29.83% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Paris Stock Exchange: ALPRE.PA

Predilife S.A.

CEO	Mr. Stephane Ragusa
IPO Date	Dec. 21, 2018
Location	France
Headquarters	39, Rue Camille Desmoulins
Employees	18
Sector	Consumers Staples
Industries Personal Care 3D Printing Biotechnology Clinical Trials Cosmetics Dental Care Medical Instruments Pharmaceuticals

Description

Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.

Key trends

Past 5 years